BR0213380A - Derivados propiÈnicos alfa-oxissubstituìdos por beta-fenila: processo para sua preparação e seu uso na preparação de compostos farmaceuticamente importantes - Google Patents
Derivados propiÈnicos alfa-oxissubstituìdos por beta-fenila: processo para sua preparação e seu uso na preparação de compostos farmaceuticamente importantesInfo
- Publication number
- BR0213380A BR0213380A BR0213380-6A BR0213380A BR0213380A BR 0213380 A BR0213380 A BR 0213380A BR 0213380 A BR0213380 A BR 0213380A BR 0213380 A BR0213380 A BR 0213380A
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- oxisubstituted
- beta
- alpha
- important compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
"DERIVADOS PROPIÈNICOS ALFA-OXISSUBSTITUìDOS POR BETA-FENILA: PROCESSO PARA SUA PREPARAçãO E SEU USO NA PREPARAçãO DE COMPOSTOS FARMACEUTICAMENTE IMPORTANTES". A presente invenção refere-se a novos derivados de ácido propiónico. Mais particularmente, a presente invenção refere-se a ácidos propiónicos alfa-oxissubstituídos por beta-fenila da fórmula geral (I). A presente invenção também refere-se a processos para a preparação de compostos da fórmula (I) e seu uso na preparação de compostos de fórmula (II).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN848CH2001 | 2001-10-16 | ||
PCT/IB2002/004274 WO2003033456A1 (en) | 2001-10-16 | 2002-10-15 | NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0213380A true BR0213380A (pt) | 2005-02-01 |
Family
ID=11097010
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0213350-4A BR0213350A (pt) | 2001-10-16 | 2002-10-15 | Derivados benzoxazina e benzotiazina e composições farmacêuticas contendo os mesmos |
BR0213380-6A BR0213380A (pt) | 2001-10-16 | 2002-10-15 | Derivados propiÈnicos alfa-oxissubstituìdos por beta-fenila: processo para sua preparação e seu uso na preparação de compostos farmaceuticamente importantes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0213350-4A BR0213350A (pt) | 2001-10-16 | 2002-10-15 | Derivados benzoxazina e benzotiazina e composições farmacêuticas contendo os mesmos |
Country Status (14)
Country | Link |
---|---|
US (2) | US20110105748A1 (pt) |
EP (2) | EP1436247A1 (pt) |
JP (2) | JP2005505617A (pt) |
CN (2) | CN1589258A (pt) |
BR (2) | BR0213350A (pt) |
CA (2) | CA2463685A1 (pt) |
HR (2) | HRP20040350A2 (pt) |
HU (2) | HUP0401649A3 (pt) |
IL (2) | IL161431A0 (pt) |
NO (2) | NO20041998L (pt) |
NZ (1) | NZ532285A (pt) |
PL (2) | PL369655A1 (pt) |
WO (2) | WO2003033456A1 (pt) |
ZA (2) | ZA200402858B (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070093476A1 (en) * | 2003-10-28 | 2007-04-26 | Bhunia Debnath | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
ITRM20050390A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
US7749995B2 (en) * | 2006-05-11 | 2010-07-06 | Janssen Pharmaceutica Nv | 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors |
WO2008079427A1 (en) | 2006-05-11 | 2008-07-03 | Janssen Pharmaceutica N.V. | 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
EP3788877A1 (en) * | 2007-04-11 | 2021-03-10 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
AU2008261102B2 (en) | 2007-06-04 | 2013-11-28 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CA2930674A1 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
HUE050267T2 (hu) | 2009-02-16 | 2020-11-30 | Nogra Pharma Ltd | Alkilamido vegyületek és alkalmazásuk |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2798911C (en) | 2010-05-19 | 2018-07-03 | Unilever Plc | Theobromine for increasing hdl-cholesterol |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
ES2652662T3 (es) | 2011-02-25 | 2018-02-05 | Merck Sharp & Dohme Corp. | Novedosos derivados de azabencimidazol cíclicos útiles como agentes antidiabéticos |
WO2013082106A1 (en) | 2011-12-02 | 2013-06-06 | The General Hospital Corporation | Differentiation into brown adipocytes |
EA030762B1 (ru) | 2012-02-09 | 2018-09-28 | Ногра Фарма Лимитед | Способы лечения фиброза |
EA201491894A1 (ru) | 2012-04-18 | 2015-02-27 | Ногра Фарма Лимитед | Способы лечения непереносимости лактозы |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CN105164220B (zh) * | 2013-04-30 | 2017-11-03 | 3M创新有限公司 | 用于制备聚(苯并噁嗪)的方法 |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3166923B1 (en) | 2014-07-10 | 2023-03-15 | SpecGx LLC | Process for preparing substituted phenylalkanes |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2020161362A1 (en) | 2019-02-08 | 2020-08-13 | Nogra Pharma Limited | Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof |
CN113968781A (zh) * | 2021-11-11 | 2022-01-25 | 上海吉奉生物科技有限公司 | 一种(s)-2-羟基-3-邻甲基丙酸的合成方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996028405A1 (fr) * | 1995-03-10 | 1996-09-19 | Nitto Chemical Industry Co., Ltd. | Procede de production de derives de 1,2-ethanediol |
NZ504106A (en) | 1998-05-27 | 2003-02-28 | Dr | Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them |
SK15092001A3 (sk) * | 1999-04-28 | 2002-05-09 | Dr. Reddy's Research Foundation | Substituované bicyklické heterocyklické zlúčeniny, spôsob ich prípravy a ich použitie ako antiobezitných a hypocholesterolemických činidiel |
SE9904421D0 (sv) * | 1999-12-03 | 1999-12-03 | Astra Ab | New compounds |
WO2002030914A1 (en) | 2000-10-12 | 2002-04-18 | Dr. Reddy's Research Foundation | Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them |
-
2002
- 2002-10-15 CA CA002463685A patent/CA2463685A1/en not_active Abandoned
- 2002-10-15 HU HU0401649A patent/HUP0401649A3/hu unknown
- 2002-10-15 PL PL02369655A patent/PL369655A1/xx not_active Application Discontinuation
- 2002-10-15 WO PCT/IB2002/004274 patent/WO2003033456A1/en active IP Right Grant
- 2002-10-15 CN CNA028227239A patent/CN1589258A/zh active Pending
- 2002-10-15 US US10/492,452 patent/US20110105748A1/en not_active Abandoned
- 2002-10-15 IL IL16143102A patent/IL161431A0/xx unknown
- 2002-10-15 CA CA002463686A patent/CA2463686A1/en not_active Abandoned
- 2002-10-15 US US10/492,454 patent/US7365064B2/en not_active Expired - Fee Related
- 2002-10-15 WO PCT/IB2002/004275 patent/WO2003033481A1/en active Application Filing
- 2002-10-15 IL IL16142902A patent/IL161429A0/xx unknown
- 2002-10-15 NZ NZ532285A patent/NZ532285A/en unknown
- 2002-10-15 CN CNA028238222A patent/CN1596249A/zh active Pending
- 2002-10-15 HU HU0401647A patent/HUP0401647A3/hu unknown
- 2002-10-15 JP JP2003536197A patent/JP2005505617A/ja active Pending
- 2002-10-15 EP EP02801466A patent/EP1436247A1/en not_active Withdrawn
- 2002-10-15 BR BR0213350-4A patent/BR0213350A/pt not_active IP Right Cessation
- 2002-10-15 JP JP2003536221A patent/JP2005527480A/ja not_active Withdrawn
- 2002-10-15 BR BR0213380-6A patent/BR0213380A/pt not_active Application Discontinuation
- 2002-10-15 EP EP02775090A patent/EP1436268A1/en not_active Withdrawn
- 2002-10-15 PL PL02369732A patent/PL369732A1/xx not_active Application Discontinuation
-
2004
- 2004-04-15 ZA ZA200402858A patent/ZA200402858B/xx unknown
- 2004-04-16 HR HR20040350A patent/HRP20040350A2/xx not_active Application Discontinuation
- 2004-04-16 HR HR20040349A patent/HRP20040349A2/hr not_active Application Discontinuation
- 2004-04-16 ZA ZA200402910A patent/ZA200402910B/en unknown
- 2004-05-14 NO NO20041998A patent/NO20041998L/no not_active Application Discontinuation
- 2004-05-14 NO NO20041994A patent/NO20041994L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2463685A1 (en) | 2003-04-24 |
US20050113368A1 (en) | 2005-05-26 |
IL161431A0 (en) | 2004-09-27 |
CN1589258A (zh) | 2005-03-02 |
HRP20040349A2 (en) | 2005-06-30 |
NZ532285A (en) | 2005-11-25 |
EP1436268A1 (en) | 2004-07-14 |
CA2463686A1 (en) | 2003-04-24 |
JP2005505617A (ja) | 2005-02-24 |
HUP0401649A3 (en) | 2007-05-29 |
NO20041998L (no) | 2004-07-02 |
WO2003033481A1 (en) | 2003-04-24 |
US7365064B2 (en) | 2008-04-29 |
EP1436247A1 (en) | 2004-07-14 |
HUP0401647A3 (en) | 2008-05-28 |
WO2003033456A1 (en) | 2003-04-24 |
CN1596249A (zh) | 2005-03-16 |
HRP20040350A2 (en) | 2005-06-30 |
ZA200402858B (en) | 2005-01-12 |
PL369732A1 (en) | 2005-05-02 |
NO20041998D0 (no) | 2004-05-14 |
HUP0401647A2 (hu) | 2004-11-29 |
NO20041994L (no) | 2004-05-14 |
PL369655A1 (en) | 2005-05-02 |
BR0213350A (pt) | 2004-10-13 |
ZA200402910B (en) | 2005-01-13 |
HUP0401649A2 (hu) | 2004-11-29 |
US20110105748A1 (en) | 2011-05-05 |
IL161429A0 (en) | 2004-09-27 |
JP2005527480A (ja) | 2005-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0213380A (pt) | Derivados propiÈnicos alfa-oxissubstituìdos por beta-fenila: processo para sua preparação e seu uso na preparação de compostos farmaceuticamente importantes | |
BR0111319A (pt) | Composto, processo para preparar um composto, uso de um composto, processo para preparar um sal de um composto, e, composto intermediário | |
BRPI0406427A (pt) | Processo para a preparação de roflumilast | |
DOP2002000512A (es) | Sales de acido succinato de 5,7,14-triazatetraciclo [10.3.1.0² ¹¹.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas | |
BR0116723A (pt) | Derivados de tioéster de ácido tiazolil acético e seu uso na preparação de compostos de cefalosporina | |
DK0422485T3 (da) | Quinoloncarboxylsyrederivater, fremgangsmåder til deres fremstilling samt deres anvendelse som antivirale midler | |
BR0215027A (pt) | Derivados de 6-aminomorfinano, processo de preparação para o mesmo e sua aplicação | |
ES2105362T3 (es) | Nuevos derivados de acidos quinolon- y naftiridoncarboxilicos. | |
BR0110430A (pt) | Processo para a preparação de um composto, composto, e, uso do mesmo | |
BR0213481A (pt) | Sondas | |
BR0212772A (pt) | Processo para a preparação de repaglinida | |
BR9705456A (pt) | Compostos heterocìclicos, processo de aminometila para sua preparação e composições farmacêuticas que os contêm. | |
PT1165485E (pt) | Processo para a preparacao de produtos intermediarios pesticidas | |
BRPI0407377A (pt) | Processo para a preparação de aminoácidos bicìclicos aromáticos e intermediários dos mesmos | |
BR0000184A (pt) | Processo para a preparação de compostos heterocìclicos | |
PT1280812E (pt) | Ciclipostinas, processo para a sua preparacao e sua utilizacao | |
BR0013799A (pt) | Processo para a preparação de um composto, e, composto | |
BR0209844A (pt) | Processo para a separação de imipenem cristalino | |
BR9907649A (pt) | Composição farmacêutica, e, processo para formular (1s,4r) -cis-4-[2-amino-6-(ciclopropilamino) -9h-purin-9-il] -2-ciclopenteno-1-metanol | |
BR0009277A (pt) | Processo de preparação de ácido propiÈnico de 3s-3-amino-3-arila e derivados deste | |
BR9713587A (pt) | Derivados de ácido 4-(1-piperazinil) benzóico, processo para preparação dos mesmos e suas aplicações terapêuticas | |
BR9714407A (pt) | Processo para preparação de derivados de 1-fenil-uracila | |
BR9808047A (pt) | Processo para a preparação de 2-nitroguanidinas 1,3-dissubstituìdas | |
WO1997022368A3 (de) | Kovalente lipid-phosphonocarbonsäure-konjugate und ihre anwendung wie antivirale arzneimittel | |
BR9902525A (pt) | Processo para compostos de ácido pirrolidinil-hidroxâmico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |